Annals of Histology & Surgical Pathology

Sign up for email alert when new content gets added: Sign up

Shingo Inaguma*
 
Department of Pathology, Aichi Medical University School of Medicine, 1-1 Yazakokarimata, Nagakute, Aichi, 480-1195, Japan, Email: [email protected]
 
*Correspondence: Shingo Inaguma, MD PhD, Department of Pathology, Aichi Medical University School of Medicine, 1-1 Yazakokarimata, Nagakute, Aichi, 480-1195, Japan, Tel: +81-561-62-3311, Fax: +81-561-61-2350, Email: [email protected]

Received Date: Nov 11, 2017 / Accepted Date: Dec 12, 2017 / Published Date: Dec 14, 2017

Citation: Inaguma S. CD274 (PD-L1)-Expression in colorectal cancer. Ann Histol Surg Pathol 2017;1(1):6-7

This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (http://creativecommons.org/licenses/by-nc/4.0/), which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes. For commercial reuse, contact [email protected]

Keywords

Colorectal cancer; CD274 (PD-L1); Immunotherapy; Biomarker

Editorial

Immunotherapy targeting immune checkpoint has emerged as a promising therapeutic strategy against cancer [1]. Aberrantly expressed CD274 (programmed cell death ligand-1, PD-L1) on tumour cells was reported to down-regulate T-cell-mediated immunity and help immune evasion of tumour cells [1]. Therapeutic antibodies targeting CD274/PDCD1 (programmed cell death 1, PD-1) axis are effective for treating distinct types of tumours [1,2]. Immunohistochemistry for CD274 has been suggested as a potential biomarker to predict efficacies of anti-CD274/PDCD1 checkpoint inhibitors [2]. Under these circumstances, several research groups, including us, has attempted to uncover the clinicopathologic profile, immunophenotype and genotype of CD274-positive colorectal carcinomas (CRCs) [3-7]. In addition to the histopathological and genetical analyses, our group tried to uncover CD274-regulation mechanism(s) using cultured CRC cells [7].

In primary CRCs, approximately 15% of cases are believed to develop through the serrated neoplasia pathway, showing mucinous and/or poorly differentiated/medullary histology, mismatch repair (MMR)-deficiency, mutational BRAF activation, and CpG island methylator phenotype [8-10). Several studies have identified significant associations between CD274 expression and characteristics of serrated neoplasia pathway-driven CRCs [3,5,6). Further immunohitochemical characterization of CD274-positive primary CRCs has revealed “stem-like” immunophenotype defined by downregulation of CDX2 (Caudal-type homeobox transcription factor 2), an intestinal differentiation marker and membranous expression of a stem cell marker ALCAM (activated leukocyte cell adhesion molecule, CD166) [3). Experimental confirmation for “stemness” of CD274-positive CRC cells has, however, never been performed.

In several types of cancers such as lung cancer, breast carcinoma, and renal cell carcinoma, recent studies have showed intra-tumour heterogeneity or differential expression of CD274 in isogenic primary and metastatic tumours [11-13). Hence, we analyzed 189 metastatic CRCs for CD274 expression and found that about 14% of metastatic CRCs showed cytoplasms-dominant CD274 expression [7]. Unlike primary tumours, this attempt showed no clear association between CD274 expression and tumour intrinsic factors such as MMR-deficiency or “stem-like” immunophenotype in metastatic CRCs [7]. Furthermore, gene mutation analyses revealed common KRAS mutations (54%) in CD274-positive metastatic CRCs [7]. These results indicate that epigenetic mechanisms, such as tumour micro environmental factor(s), might dominantly regulate CD274 expression in metastases.

Based on these results, we tested interferon-γ (IFNγ) and transforming growth factor-β1 (TGF-β1) famous soluble factors secreted from stromal cells, for CD274 regulation in five colon cancer cell lines. As a result, all of the cell lines were responsive to exogenous INFγ for CD274 up-regulation through JAK-STAT pathway, regardless of their subtypes such as MMR-deficiency or RAS/BRAF mutation status. On the other hand, CD274 regulation by TGF-β1 varied: up-regulation, down-regulation, and no clear change [7]. These experimental results suggest that INFγ and/or TGF-β1 within tumour micro environment could modulate CD274 expression.

In summary, recent studies have identified significantly distinct characteristics in CD274-positive primary and metastatic CRCs. Immunohistochemical evaluation of metastases should be considered in planning CD274/PDCD1 axis inhibitors therapy so that non-optimal use of the drugs would be avoided. Further molecular biological studies are needed to understand a complicated CD274 regulating mechanism in CRCs.

Conflict of Interest

The author has disclosed no relationships with, or financial interest in, any commercial companies pertaining to this article.

References

 
Top